Low prevalence of infection by HTLV-I in populations at risk for HIV in Djibouti. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Low prevalence of infection by HTLV-I in populations at risk for HIV in Djibouti.

Ann Inst Pasteur Virol. 1988 Oct-Dec;139(4):443-7. Unique Identifier : AIDSLINE MED/89105473
Fox E; Constantine NT; Abbatte EA; Said-Salah; Rodier G; US Naval Medical Research Unit 3 (NAMRU-3), Cairo.

Abstract: In order to determine whether HTLV-I (a recently discovered retrovirus causing T-cell leukaemias and lymphomas, as well as tropical spastic paraparesis) was present in Djibouti in 1988, we investigated 576 subjects belonging to various groups at risk of acquiring HIV, a related retrovirus transmitted analogously to HTLV-I. Sera were screened by a commercial agglutination assay and confirmation of repeatedly reactive sera was performed by specific Western blot analysis. Four sera were strongly positive for HTLV-I by Western blotting, while one serum displayed equivocal reactivity. All positive sera came from young women who engaged in prostitution. This accounted for an HTLV-I seropositivity rate of 0.7% (95% CI, 0.03-1.4%) in the total study population and 1.2% (95% CI, 0.02-2.4%) in the population engaged in prostitution. We concluded that in Djibouti in June 1988, HTLV-I was present but that the prevalence of infection in high risk individuals was very low.
Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY Africa, Eastern Blotting, Western Human HTLV-I Antibodies/ANALYSIS HTLV-I Infections/*EPIDEMIOLOGY/IMMUNOLOGY Risk Factors Support, U.S. Gov't, Non-P.H.S. JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/epidemiologyafrica,easternblotting,westernhumanhtlv-iantibodies/analysishtlv-iinfections/KWDepidemiology/immunologyriskfactorssupport,uKWDsKWDgov't,non-pKWDhKWDsKWDjournalarticle
890530
M8950650

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .